DPP3 Biomarker Detection for Coronavirus Therapy Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and managing patients with coronavirus infections lack effective tools to predict life-threatening deterioration, severity, or therapy success, particularly in relation to dipeptidyl peptidase 3 (DPP3) levels in bodily fluids.
Innovation Solution
A method involving the determination of DPP3 levels in bodily fluids, comparison to pre-determined thresholds, and correlation with risk assessment or therapy outcomes, using specific capture binders and substrates to quantify DPP3 activity, with the option of using DPP3 inhibitors for intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DPP3 levels are determined in bodily fluids, then prediction of adverse events and therapy success is improved, but device complexity and measurement precision requirements increase
Solution Approach 1:
The patent employs capture binders as intermediary molecules that specifically interact with DPP3 in bodily fluids. These binders facilitate the detection and measurement of DPP3 levels through standardized assays, enabling reliable prediction of adverse events and therapy outcomes while managing the complexity of the measurement system through well-established biochemical interaction mechanisms.
2Measurement precision
If DPP3 activity is quantified using capture binders and substrates, then measurement precision is improved, but ease of operation decreases
Solution Approach 1:
The patent incorporates substrate conversion measurements that provide feedback on DPP3 activity levels. By measuring the conversion of substrates to products through enzymatic reactions, the system achieves precise quantification of DPP3 activity while maintaining operational simplicity through automated readout and interpretation of the feedback signals.
3Reliability
If DPP3 levels are monitored in relation to clinical outcomes, then therapy guidance is improved, but loss of time in diagnosis and management increases
Solution Approach 1:
The patent enables preliminary determination of DPP3 levels and prediction of adverse events before critical clinical decisions need to be made. By establishing baseline DPP3 concentrations and monitoring changes over time, the system provides advance warning and guidance, allowing clinicians to prepare interventions in advance and reducing overall management time while improving therapeutic accuracy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables accurate prediction of adverse events and therapy success, allowing for targeted patient management and stratification, particularly for SARS-CoV-1 and SARS-CoV-2 infections, by effectively monitoring DPP3 levels and activity in relation to clinical outcomes.
Implementation Method 1
DPP3 is a zinc-depending exo-peptidase belonging to the peptidase family M49. It has a broad substrate specificity for oligopeptides from three/four to ten amino acids of various compositions and is also capable of cleaving after proline. DPP3 is known to hydrolyze dipeptides from the N-terminus of its substrates
Implementation Method 2
two assays were generated, characterized, and validated to specifically detect DPP3 in human bodily fluids (e.g., blood, plasma, serum): a luminescence immunoassay (LIA) to detect DPP3 protein concentration
Implementation Method 3
an enzyme capture activity assay (ECA) to detect specific DPP3 activity
Data Source
AI summary
Subject matter of the present invention is a method for (a) diagnosing or predicting the risk of life-threatening deterioration or an adverse event or (b) diagnosing or prognosing the severity or (c) predicting or monitoring the success of a therapy or intervention or (d) therapy guidance or therapy stratification or (e) patient management in a patient infected with a coronavirus, the method comprising:determining the level of dipeptidyl peptidase 3 (DPP3) in a sample of bodily fluid of said patient,comparing said level of determined DPP3 to a pre-determined threshold, andcorrelating said level of determined DPP3 with the risk of life-threatening deterioration or an adverse event, orcorrelating said level of determined DPP3 with the severity, orcorrelating said level of determined DPP3 with the success of a therapy or intervention, orcorrelating said level of DPP3 with a certain therapy or intervention, orcorrelating said level of DPP3 with the management of said patient.Subject matter of the present invention is an inhibitor of the activity of DPP3 for use in therapy or intervention in a patient infected with a coronavirus.